Cost-Effectiveness of Trastuzumab With or Without Chemotherapy as Adjuvant Therapy in HER2-Positive Elderly Breast Cancer Patients: A Randomized, Open-Label Clinical Trial, the RESPECT Trial.

Yuki TakumotoTakeru ShiroiwaKojiro ShimozumaHiroji IwataMasato TakahashiShinichi BabaKokoro KobayashiYasuhiro HagiwaraTakuya KawaharaYukari UemuraHirofumi MukaiNaruto TairaMasataka Sawaki

Published in: Clinical drug investigation (2022)

The base-case analysis suggests that AdjCT with trastuzumab + chemotherapy is likely to be a cost-effective choice for patients with HER2-positive BC aged 70 years or older. However, the sensitivity analysis suggested uncertainty regarding the cost-effectiveness of trastuzumab + chemotherapy.

Keyphrases

clinical trial
open label
epidermal growth factor receptor
phase ii
study protocol
phase iii
metastatic breast cancer
middle aged
physical activity
community dwelling
squamous cell carcinoma
randomized controlled trial
phase ii study
tyrosine kinase
data analysis